Literature DB >> 15989710

A randomized phase III study of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin as salvage chemotherapy followed by posttransplantation rituximab maintenance therapy versus observation for treatment of aggressive B-Cell and T-Cell non-Hodgkin's lymphoma.

Michael Crump1, Lois Shepherd, Boris Lin.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15989710     DOI： 10.3816/clm.2005.n.030

Source DB:  PubMed          Journal:  Clin Lymphoma        ISSN： 1526-9655


× No keyword cloud information.
  3 in total

1.  Phase 2 trial of combined cisplatin, etoposide, gemcitabine, and methylprednisolone (PEGS) in peripheral T-cell non-Hodgkin lymphoma: Southwest Oncology Group Study S0350.

Authors:  Daruka Mahadevan; Joseph M Unger; Catherine M Spier; Daniel O Persky; Fay Young; Michael LeBlanc; Richard I Fisher; Thomas P Miller
Journal:  Cancer       Date:  2012-07-25       Impact factor: 6.860

2.  Strategies for relapsed peripheral T-cell lymphoma: the tail that wags the curve.

Authors:  Matthew A Lunning; Alison J Moskowitz; Steven Horwitz
Journal:  J Clin Oncol       Date:  2013-04-29       Impact factor: 44.544

3.  Salvage therapy with mitoxantrone, etoposide, bleomycin and dexamethasone for refractory or relapsed aggressive non-Hodgkin's lymphoma patients with a poor performance status or comorbidity.

Authors:  Xuede Lin; Xi Shi; Wucha Zeng; Min Zheng; Liming Huang
Journal:  Oncol Lett       Date:  2014-09-09       Impact factor: 2.967
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.